Osteolytic metastasis detected in a patient with lung carcinoma by F18-FDG PET by González Sistal, Ángel et al.
Abstract
Figure 1. Tc-99m MDP whole body bone scan
were performed and resulted a normal
scintiscan.
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We present a 53-year-old man with a vocal cord paralysis observed as a primary manifestation of
lung carcinoma. Tc-99m MDP whole body bone scan was performed and resulted in a normal scintiscan. The
bone scan did not reveal any suspicious foci of uptake. The possibility of bone metastasis was taken into
consideration. A whole body F18-FDG-PET scan showed intense uptake in the left upper lung corresponding to
the primary tumor. A bronchial biopsy confirmed infiltration by small cell lung carcinoma (SCLC). SCLC is
composed of poorly differentiated, rapidly growing cells with diseases usually occurring centrally rather than
peripherally. It metastasizes early. The whole-body F18-FDG-PET scan clearly demonstrated a focus of
increased uptake in the second lumbar vertebral body suspicious for osteolytic metastasis. A lytic bone
metastasis was confirmed by MRI. The patient then received therapy and underwent follow up abdominal CT.
The scan showed blastic changes in the L2 vertebra suggesting response to treatment.
INTRODUCTION
Bone metastases are diagnosed at initial presentation in 4%–60% of patients with lung cancer. Bone pain is usually
considered an indicator of skeletal metastases, but up to 40% of lung cancer patients with proven bone metastases
are asymptomatic. Clinical staging at presentation has been performed by means of CT of the thorax through the
liver and adrenals, CT or MRI of the brain, and scintgraphy for assessment of bone involvement. This staging
algorithm remains the most commonly used in places where 18F-FDG PET is not a routine staging modality of lung
cancer. If necessary, scintigraphy can be complemented by CT or regional MRI for further assessment of unclear
lesions. 18F-FDG PET and PET/CT were recently reported to be of value in assessing the presence of soft-tissue
and bone spread in patients with lung cancer. They reported that 18F-FDG PET had a high positive predictive
value and a lower false-positive rate.
The two main histopathologic categories for lung malignancies are
small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). In both categories, their clinical behaviors and treatments
are different. SCLC accounts for the minority (14%) of lung cancer
cases and is composed of poorly differentiated, rapidly growing cells
with diseases usually occurring centrally rather than peripherally. It
metastasizes early. Management for SCLC is nonsurgical, and
therapy is via chemotherapy alone or in combination with radiotherapy
[1].
CASE REPORT
Bone scintigraphy is the method
used to screen the whole body for
bone metastasis in patients with
malignancies. We present a 53-
year-old man with a 4-month history
of progressive dysphonia. Patient
was referred to a consultant otolaryngologist for clinical examination. Vocal cord
paralysis was observed as a primary manifestation of left upper lung carcinoma
elucidated by chest radiograph. Tc-99m MDP whole body bone scan wase
Figure 2. A whole body F18
fluorodeoxyglucose (FDG) PET
scan showed intense uptake in
the left upper lung corresponding
to the primary tumor with a
maximum standardized uptake
value (SUVmax) of 19.7 (red
arrow). Lung cancer was
associated to paratracheal and
subcarinal lymph nodes.
Pathological lymph nodes are
clearly demonstrated in clavicular
regions (left SUVmax: 16.7; and
right SUV max:10.4).
Figure 3. The whole-body F18 FDG PET scan clearly
demonstrated a focus of increased uptake in the second lumbar
vertebral body (red cross) which was suspicious for osteolytic
metastasis and no other bony lesion was identified.
performed and resulted in a normal scintiscan (Figure 1). The bone scan did not
reveal any suspicious foci of uptake. Bone metastases develop in 30% of all
patients with cancer. Bone metastases are usually located in the axial skeleton.
Scintigraphy does not detect pure lytic metastasis when bone turnover is slow or
when the site is avascular [2]. The possibility of bone metastasis should be taken
into consideration in patients with an underlying cancer history for avoiding delay
or misdiagnosis.
A whole body F18
fluorodeoxyglucose
(FDG) PET scan
showed intense
uptake in the left
upper lung
corresponding to the primary tumor with a maximum
standardized uptake value (SUVmax) of 19.7 (Figure
2). Lung cancer was associated to paratracheal and
subcarinal lymph nodes. Pathological lymph nodes
were clearly demonstrated in clavicular regions (left
SUVmax: 16.7; and right SUVmax: 10.4).
Bronchial biopsy of the upper left lobe confirmed
infiltration by small cell lung carcinoma (SCLC). Cancer cells expressed: TTF1, CD56, p53, synaptophysin and
chromogranin.
The whole-body F18 FDG PET scan clearly demonstrated a focus of increased uptake in the second lumbar
vertebral body (Figure 3) which was suspected for osteolytic metastasis and no other bony lesion was identified. An
osteolytic bone metastasis was confirmed by MRI. Thus, FDG PET is useful for detecting osteolytic metastasis in
patients with a malignancy [3] [4]. PET can be a sensitive modality for diagnosing and monitoring bone metastasis
[5].
Selected axial slice of diagnostic abdominal CT scan
showed the presence of oteolytic metastasis in L2
vertebra (Figure 4A). The patient received radiation
therapy and chemotherapy. Four weeks later the
patient underwent a second follow up CT, and the
scan showed blastic changes in the posterior edge of
the L2 vertebra (Figure 4B) suggesting response to
treatment [6].
DISCUSSION
2-deoxy-2-[18F]-fluoro-D-glucose or
fluorodeoxyglucose (18FDG) has been used to
measure glucose metabolism in many types of
primary cancer and can be useful for distinguishing
benign bone lesions from malignant ones. It is an
analog of glucose and represents the most widely
used PET radiotracer in daily practice. The
mechanism of uptake in tumor cells consists of the
diffusion facilitated by glucose transporters (GLUTs),
phosphorylation by hexokinase and subsequent
Figure 4. A) Selected axial slice of diagnostic abdominal CT scan,
perfomed on March 8, 2011, showed the presence of oteolytic
metastasis in L2 vertebra (red arrow). B) The patient received
radiation therapy and chemotherapy. Four weeks later the patient
underwent a second follow up CT, and the scan showed blastic
changes in the posterior edge of the L2 vertebra (red arrow)
suggesting response to treatment [6].
metabolic trapping within the cell. It is a reflection of
glucose metabolism consumption on the tissue level.
Although it is a very sensitive marker, it is not very
specific, since any increase in tissue uptake of
18FDG is not always synonymous with cancer. The
main clinical application of this technique consists of
diagnosing, staging and restaging of various cancer
types. It is very effective in detecting metastases of
breast, lung, esophagus, colon, thyroid, head and
neck, melanoma and lymphoma [7].
Bone metastases are well despicted on CT. But the
usefulness of CT in detecting early deposits in bone
marrow is limited. Although CT is superior to radiography some advanced destructive lesions on trabecular bone
may not be visible in the absence of cortical bone involvement. Therefore CT is less apparent than the marrow
changes visualized on MRI [6]. CT is also better than radiography and scintigraphy for depicting lesions in the spine
and calvarium. CT is useful in guiding needle biopsy in bones such as vertebrae or ilia. When assessing the
therapeutic response, sclerosis of a lytic metastasis on CT suggests a response to treatment. Notwithstanding, lysis
or the appearance of new lysis or an increase in the size of blastic lesion represents a disease progression [8].
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